These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27504952)

  • 1. Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank.
    Kliemann DA; Tovo CV; Gorini da Veiga AB; Machado AL; West J
    PLoS One; 2016; 11(8):e0159924. PubMed ID: 27504952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database.
    Kliemann DA; Tovo CV; da Veiga AB; de Mattos AA; Wood C
    World J Gastroenterol; 2016 Oct; 22(40):8910-8917. PubMed ID: 27833382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors.
    Cento V; Mirabelli C; Salpini R; Dimonte S; Artese A; Costa G; Mercurio F; Svicher V; Parrotta L; Bertoli A; Ciotti M; Di Paolo D; Sarrecchia C; Andreoni M; Alcaro S; Angelico M; Perno CF; Ceccherini-Silberstein F
    PLoS One; 2012; 7(7):e39652. PubMed ID: 22792183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance-associated variants in HCV subtypes 1a and 1b detected by Ion Torrent sequencing platform.
    Gaspareto KV; Ribeiro RM; de Mello Malta F; Gomes-Gouvêa MS; Muto NH; Romano CM; Mendes-Correa MC; Carrilho FJ; Sabino EC; Rebello Pinho JR
    Antivir Ther; 2016; 21(8):653-660. PubMed ID: 27314166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.
    Alves R; Queiroz AT; Pessoa MG; da Silva EF; Mazo DF; Carrilho FJ; Carvalho-Filho RJ; de Carvalho IM
    J Viral Hepat; 2013 Jun; 20(6):414-21. PubMed ID: 23647958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.
    McPhee F; Hernandez D; Zhou N; Ueland J; Yu F; Vellucci V; Huang X; Wang X; Ishikawa H; Karino Y; Kumada H
    Antivir Ther; 2018; 23(1):53-66. PubMed ID: 28594332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unexpected Replication Boost by Simeprevir for Simeprevir-Resistant Variants in Genotype 1a Hepatitis C Virus.
    Murai K; Shimakami T; Welsch C; Shirasaki T; Liu F; Kitabayashi J; Tanaka S; Funaki M; Omura H; Nishikawa T; Sumiyadorj A; Honda M; Kaneko S
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.
    Fridell RA; Qiu D; Wang C; Valera L; Gao M
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3641-50. PubMed ID: 20585111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia.
    Aissa Larousse J; Trimoulet P; Recordon-Pinson P; Papuchon J; Azzouz MM; Ben Mami N; Cheikh I; Triki H; Fleury H
    J Med Virol; 2014 Aug; 86(8):1350-9. PubMed ID: 24760718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of hepatitis C virus for subtype determination and resistance-associated substitutions detection among Chinese voluntary blood donors.
    Jiang X; Lv X; Chang L; Yan Y; Ji H; Sun H; Guo F; Rodgers MA; Yin P; Wang L
    Antiviral Res; 2020 Sep; 181():104871. PubMed ID: 32717286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in direct acting antiviral naive patients.
    Grammatikos G; Jabara CB; Ahmad MQ; Herrmann E; Zeuzem S; Welsch C
    Antivir Ther; 2014; 19(5):455-61. PubMed ID: 24457994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of resistance-associated substitutions in hepatitis C virus sequences from Kyrgyzstan].
    Kartashov MY; Svirin KA; Bekbolotov AA; Momusheva KT; Iskanova BM; Solpueva AS; Motorov UT; Narmatova EB; Krivosheina EI; Gladysheva AV; Chub EV; Gashnikova NM
    Vopr Virusol; 2023 Jul; 68(3):265-270. PubMed ID: 37436417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6.
    Dvory-Sobol H; Han B; Lu J; Yu M; Beran RK; Cheng G; Martin R; Svarovskaia E; Mo H
    J Viral Hepat; 2019 Aug; 26(8):991-1001. PubMed ID: 31009123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.
    Ramirez S; Mikkelsen LS; Gottwein JM; Bukh J
    Gastroenterology; 2016 Nov; 151(5):973-985.e2. PubMed ID: 27453546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors.
    Ferraro D; Urone N; Di Marco V; Craxì A
    Infect Genet Evol; 2014 Apr; 23():80-5. PubMed ID: 24508244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
    Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
    Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine.
    Ikram A; Obaid A; Awan FM; Hanif R; Naz A; Paracha RZ; Ali A; Janjua HA
    Antiviral Res; 2017 Jan; 137():112-124. PubMed ID: 27984060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on hepatitis C virus resistance to direct-acting antiviral agents.
    Poveda E; Wyles DL; Mena A; Pedreira JD; Castro-Iglesias A; Cachay E
    Antiviral Res; 2014 Aug; 108():181-91. PubMed ID: 24911972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.
    Plaza Z; Soriano V; Vispo E; del Mar Gonzalez M; Barreiro P; Seclén E; Poveda E
    Antivir Ther; 2012; 17(5):921-6. PubMed ID: 22436385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.